Price alone won't push weight-loss, diabetes drug semaglutide sales: Doctors

Leading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenmark, and Torrent were among the first to roll out generic semaglutide on the first day of patent expiry of Novo Nordisk’s innovator molecule on Saturday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/my3X8YP
via IFTTT

Read More

India is well positioned to attract future investments, says Eli Lilly's Patrick Johnson

Faster ApprovalsFaster, predictable, and globally aligned clinical trial approvals are critical for India to attract high-value research and strengthen scientific capability and capacityPatrick JohnsonExecutive Vice President of Eli Lilly and Company and President of Lilly International

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SmdTnVf
via IFTTT

Read More

Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 Diabetes

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive DCGI approval for this GLP-1 receptor agonist. Available in 2mg and 4mg strengths, the once-weekly subcutaneous injection demonstrated non-inferior efficacy and a comparable safety profile in Phase III studies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eMFf0PI
via IFTTT

Read More

Natco, Eris Life to launch slimming shots in both Vial and Pen formats

Natco Pharma and Eris Lifesciences are launching generic semaglutide weight-loss injections. The companies are introducing both vial and pen formats. This move aims to make the treatment more affordable. Vials will be available first, targeting a wider patient base. Pens are expected later for metropolitan markets. This strategy offers patients pricing flexibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wPXzTLW
via IFTTT

Read More

Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expires

Natco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the innovator's drug. The company aims to make this treatment more accessible to patients across India. Other pharmaceutical companies are also preparing to launch their generic versions. This development promises significant cost savings for consumers seeking this medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSxs32K
via IFTTT

Read More

Natco launches Rs 1,290 semaglutide in India, undercuts diabetes drug prices

Natco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment more accessible. The drug is available at a much lower price compared to existing options. This move is expected to benefit a large number of diabetic patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/InWTzCi
via IFTTT

Read More

Small pharma companies seek price caps on inputs as costs surge

Indian pharmaceutical units face a severe crisis. Input costs have surged by 200-300 percent. This is due to global conflicts disrupting raw material supply. The Himachal Drug Manufacturers Association seeks government intervention. They want emergency price controls and a crisis task force. This aims to protect the industry and ensure medicine availability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nXC5bIZ
via IFTTT

Read More